New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone palmitate 117mg equivalent to 75 mg paliperidone base;   - suspension for injection - 75 mg - active: paliperidone palmitate 117mg equivalent to 75 mg paliperidone base   excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - invega sustenna® is indicated for the acute and maintenance treatment of schizophrenia in adults.

United States - English - NLM (National Library of Medicine)

ascent pharmaceuticals, inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. paliperidone

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - paliperidone palmitate 156 mg/ml equivalent to paliperidone 100 mg/ml - suspension for injection - 100 mg - active: paliperidone palmitate 156 mg/ml equivalent to paliperidone 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - paliperidone advz is indicated for the acute and maintenance treatment of schizophrenia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - paliperidone palmitate 156 mg/ml equivalent to paliperidone 100 mg/ml - suspension for injection - 150 mg - active: paliperidone palmitate 156 mg/ml equivalent to paliperidone 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - paliperidone advz is indicated for the acute and maintenance treatment of schizophrenia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml - suspension for injection - 25 mg - active: paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - paliperidone advz is indicated for the acute and maintenance treatment of schizophrenia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml - suspension for injection - 50 mg - active: paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - paliperidone advz is indicated for the acute and maintenance treatment of schizophrenia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml - suspension for injection - 75 mg - active: paliperidone palmitate 156 mg/ml equivalent to paliperidone 100mg/ml excipient: citric acid monohydrate dibasic sodium phosphate macrogol 4000 monobasic sodium phosphate monohydrate polysorbate 20 sodium hydroxide water for injection - paliperidone advz is indicated for the acute and maintenance treatment of schizophrenia in adults.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients t

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1560 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1092 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.